May 30, 2018
ALBANY, N.Y. (PR NEWSWIRE) – AMRI’s Michele Luche, vice president, Discovery Services, will be participating in a panel discussion on bridging the gap between early promise and clinic-ready compounds at the 2018 BIO International Convention, June 4-7 at the Boston Convention and Exhibition Center in Boston.
The interactive panel will discuss considerations would-be entrepreneurs need to convince investors and potential partners that they have de-risked their programs as much as possible and share case studies of successes and failures. The session titled, “What Drug Hunters Look for in Early Stage Assets,” will include experienced entrepreneurs, pharma developers and service providers.
“Early assets offer significant promise for targeting new avenues to treat disease in ways that have yet to be tapped by established companies; however, a molecule that hits a target may still carry significant discovery and development risks,” said Michele Luche. “The experienced panelists will bring a range of perspectives on this important topic.”
Session Name: What Drug Hunters Look for in Early Stage Assets
Date/Time: June 4, 2018, 1:00 PM – 2:15 PM ET
Location: Boston Convention and Exhibition Center, Room 206AB
Moderator: Ed Silverman, STAT senior writer and Pharmalot columnist.
Panelists: Michele Luche; Daniel P. Gold, PhD., President & Chief Executive Officer, MEI Pharma; Margaret Porter Scott, Director, Biochemical and Cellular Pharmacology, Genentech; and Jake McDonald, Ph.D., Chief Scientific Officer, Lovelace Biomedical.
To arrange and schedule a meeting with AMRI (Booth No. 1011) while attending BIO, please make a request here.
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.